New coordination system aims to cut cancer treatment delays
NCT ID NCT07180901
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a new care coordination system called PRONTO-HN for head and neck cancer patients. The system uses a risk model to identify patients likely to need radiation after surgery and then coordinates appointments and alerts to reduce delays. Researchers will compare 85 patients before and after the system is implemented to see if more patients start radiation within 42 days of surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Proactive care coordination system (PRONTO-HN)
- What this could lead to
- If successful, this system could help more head and neck cancer patients start radiotherapy on time after surgery, potentially improving survival and reducing recurrence.
- What could go wrong
- This is a small pilot study at one hospital, so results may not apply elsewhere. The intervention is administrative and may not reduce delays as expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 85 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Oct 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All adult patients (age 18 or older). * Pathologically confirmed oral cavity or laryngeal squamous cell carcinoma. * Diagnosed from July 2024 to September 2026. * With planned primary intention surgical resection. * With or without adjuvant therapy. * Treated at the Centre Hospitalier de l'Université de Montréal. Exclusion Criteria: * Patients who do not end up receiving surgery. * S-PORT \> 180 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head & neck squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier de l'Université de Montréal
RECRUITINGMontreal, Quebec, H2X 0C1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartphone program aims to boost hope and recovery in oral cancer survivors
- Glowing light could spot oral cancer before it starts
- Can immune markers predict success of docetaxel chemoradiotherapy?
- New drug duo offers hope for hard-to-treat head and neck cancer
- Collagen patch after oral cancer surgery: does it help you swallow and speak?
- Peptide vaccine shows promise in head and neck cancer trial